Also known as: advanced squamous cell carcinoma of the anal canal, SCAC
Squamous cell carcinoma of the anal canal is the most common histologic type of anal cancer and arises from squamous epithelium in the anal canal region. It is strongly associated with HPV infection and is treated with multimodality approaches.
Incyte received a Complete Response Letter from the FDA for Zynyz in lung cancer due to third-party manufacturing issues, while the EMA recommended approval for the drug in anal cancer treatment based on Phase 3 trial data.
New combination therapies demonstrate improved outcomes in advanced anal and colorectal cancers, with retifanlimab plus chemotherapy approved for anal cancer and onvansertib showing strong efficacy signals in RAS-mutated colorectal cancer.
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in second-line KRAS-mutant microsatellite-stable metastatic colorectal cancer, based on clinical data showing a 33% response rate and median overall survival of 27 months versus 11.2 months with standard treatment.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07455942 |
Towards an Understanding of Barriers and Delays in the Diagnosis of Anal Cancer |
NOT_YET_RECRUITING | |
| NCT06910137 |
An Early Access Program Guideline to Provide Access to Retifanlimab (INCMGA00012) Together With Carboplatin and Paclitaxel for Squamous Carcinoma of the Anal Canal (SCAC) |
AVAILABLE | |
| NCT05661188 |
Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS) |
RECRUITING | PHASE2 |
| NCT05201105 |
Tumor Recurrence After Abdominal-perineal Amputation in Squamous Cell Carcinoma of the Anus |
COMPLETED | |
| NCT04472429 |
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). |
COMPLETED | PHASE3 |
